Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: jerryriti who wrote (1028)	10/22/1999 1:48:00 PM
From: LLCF	Read Replies (1) \| Respond to of 1728

<Their GeneChip allows researchers to do their screening faster and more efficiently, i.e., enormous cost savings and represents a true paradigm shift in drug research.> Agreed, this is a 'discontinous innovation' as the Gorilla gamers say. <I did take the win against Incyte as indicating that they have a clear lead and will defend their intellectual property i.e. GeneChip is proprietary!> There is no 'win'... the case goes to trail middle of next year at earliest I believe. <More importantly, I believe that as their GeneChip system is more widely used(revenues increasing) they are more readily assured of return business> I hear you there... nothing like a nice lead! Thanks, DAK